Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2019 Jul 1.

Published in final edited form as: Neurogastroenterol Motil. 2018 Feb 28;30(7):e13313. doi: 10.1111/nmo.13313

Box plots comparing the changes in gastric emptying and weight loss at 5 weeks compared to baseline among the various genotypes and drug vs. placebo.

A. Effects of liraglutide vs. placebo on gastric emptying at 5 weeks based on genetic variants of GLP1 R (rs6923761) and TCF7L2 (rs7903146) genes. Note that the median prolongation of GE T_1/2 was 80.0 (48.0, 211.0) in the AA_AG genotype and 55.5 (24.0, 105.0) in the GG genotype group for GLP-1 R (rs6923761).

B. Effects of liraglutide vs. placebo on weight loss at 5 weeks based on genetic variants of GLP1R (rs6923761) and TCF7L2 (rs7903146) genes. There were no significant associations of genotypes tested with weight loss.

Box plots comparing the changes in gastric emptying and weight loss at 5 weeks compared to baseline among the various genotypes and drug vs. placebo.

A. Effects of liraglutide vs. placebo on gastric emptying at 5 weeks based on genetic variants of GLP1 R (rs6923761) and TCF7L2 (rs7903146) genes. Note that the median prolongation of GE T_1/2 was 80.0 (48.0, 211.0) in the AA_AG genotype and 55.5 (24.0, 105.0) in the GG genotype group for GLP-1 R (rs6923761).

B. Effects of liraglutide vs. placebo on weight loss at 5 weeks based on genetic variants of GLP1R (rs6923761) and TCF7L2 (rs7903146) genes. There were no significant associations of genotypes tested with weight loss.